Fisher & Paykel HealthcareFRA:FPLB +1.60%85 EV-to-FCF is 47.71 as of Jun. 30, 2026, which is 34% below its 10-year median of 72.10. GuruFocus rates FRA:FPLB with a GF Score™ of 85/100 and a GF Value™ of €21.68 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 419 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks worse than 75.66% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Fisher & Paykel Healthcare's Enterprise Value is €11,253 Mil.
Fisher & Paykel Healthcare's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €236 Mil. Therefore, Fisher & Paykel Healthcare's EV-to-FCF for today is 47.71.
The historical rank and industry rank for Fisher & Paykel Healthcare's EV-to-FCF or its related term are showing as below:
FRA:FPLB'
s EV-to-FCF Range Over the Past 10 Years
Min: 31.54 Med: 72.1 Max: 599.89
Current: 47.58
During the past 13 years, the highest EV-to-FCF of Fisher & Paykel Healthcare was 599.89. The lowest was 31.54. And the median was 72.10.
FRA:FPLB's EV-to-FCF is ranked worse than 75.66% of 419
companies
in the Medical Devices & Instruments industry
Industry Median: 22.57
vs FRA:FPLB: 47.58
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fisher & Paykel Healthcare's PE Ratio (TTM) for today is calculated as:
Fisher & Paykel Healthcare's share price for today is €19.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fisher & Paykel Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.399.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Fisher & Paykel Healthcare EV-to-FCF Related Terms
Fisher & Paykel Healthcare EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's EV-to-FCF falls into.
Fisher & Paykel Healthcare's current Enterprise Value is €11,253 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fisher & Paykel Healthcare's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €236 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (FRA:FPLB) has a EV-to-FCF of 47.71 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fisher & Paykel Healthcare and its competitors. This is 34% below median its historical median of 72.10. Over the past decade, Fisher & Paykel Healthcare's EV-to-FCF has ranged from 31.54 to 599.89. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #317 out of 419 companies in the Medical Devices & Instruments industry, placing it in the top 75.7%.
Is Fisher & Paykel Healthcare's EV-to-FCF too high?
Fisher & Paykel Healthcare's current EV-to-FCF of 47.71 is 34% below median its 10-year median of 72.10. Over the past 10 years, this metric has ranged from a low of 31.54 to a high of 599.89. The Medical Devices & Instruments industry median EV-to-FCF is 22.57. Fisher & Paykel Healthcare's value of 47.71 is 111.4% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #317 out of 419 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #317 out of 419 companies for EV-to-FCF. This places Fisher & Paykel Healthcare in the lower half of its industry. The industry median EV-to-FCF is 22.57. Fisher & Paykel Healthcare's value of 47.71 is 111.4% above this benchmark. Historically, Fisher & Paykel Healthcare's own EV-to-FCF has ranged from 31.54 to 599.89 over the past decade. While the company's 10-year median is 72.10 vs. the industry median of 22.57, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.57, based on 419 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current EV-to-FCF of 47.71 is 111.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current EV-to-FCF is 47.71, which is 34% below median its own 10-year median of 72.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (FRA:FPLB) is currently considered Modestly Undervalued. The stock's GF Value™ is €21.68, compared to a current price of €19.10 — trading 11.9% below its estimated fair value. The current EV-to-FCF is 47.71, which is 34% below median its 10-year median of 72.10 and 111.4% above the Medical Devices & Instruments industry median of 22.57. Fisher & Paykel Healthcare's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Fisher & Paykel Healthcare (FRA:FPLB), the current EV-to-FCF is 47.71 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (FRA:FPLB) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of €19.10 is trading 11.9% below its estimated GF Value™ of €21.68.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for FRA:FPLB:
EV-to-FCF: 47.71 (34% below median its 10-year median of 72.10)
GF Value™: €21.68 vs. price of €19.10 (11.9% below fair value)
Industry Position: 111.4% above the Medical Devices & Instruments median (#317 of 419)
No single metric tells the full story. See the FRA:FPLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
85GF Score
Get the complete analysis for FRA:FPLB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FPLB has been successfully added to your 
